After Versanis success, Aditum launches Celexor Bio with autoimmune drug from Acelyrin partner Inmagene
The biotech licensing whizzes at Aditum Bio, the VC firm from ex-Novartis CEO Joe Jimenez and Mark Fishman, have created their 10th company by nabbing the rights to a preclinical autoimmune drug.
The new startup, Celexor Bio, will pay an undisclosed upfront and up to $287 million in biobucks to San Diego-based Inmagene Biopharmaceuticals, which will also get an equity stake in the new biotech and potential royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.